Evidence map›Paper›PMID 39297892›Full record

ArticleCEN case reports2025

MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during treatment of plaque psoriasis with bimekizumab.

Takuya Sugiura, Tomohito Doke, Akihito Tanaka, Yuka Sato, Kayaho Maeda, Kazuhiro Furuhashi, Noritoshi Kato, Tomoki Kosugi, Shoichi Maruyama

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Takuya SugiuraDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0009-0002-7952-4175
Tomohito DokeDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. tomorurira0220@gmail.com.
Akihito TanakaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuka SatoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kayaho MaedaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuhiro FuruhashiDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Noritoshi KatoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoki KosugiDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 75-year-old man presented with MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during the treatment of plaque psoriasis vulgaris with bimekizumab. Bimekizumab, an anti-IL17 monoclonal antibody, was regularly administered to control the activity of plaque psoriasis. After receiving the sixth COVID-19 vaccine, his kidney function rapidly declined over the course of weeks. Urinalysis showed microscopic hematuria and proteinuria with deformed red blood cells and granular cast. The immunology test was positive for MPO-ANCA. The patient was clinically diagnosed with MPO-ANCA-associated glomerulonephritis. As the patient lost his appetite and developed lower extremity edema with low eGFR (< 15 ml/min/1.73m

Indexed as

Antibodies, Antineutrophil CytoplasmicAntibodies, Monoclonal, HumanizedCOVID-19COVID-19 VaccinesGlomerulonephritisPsoriasisAgedHumansImmunosuppressive AgentsMaleMethylprednisolonePeroxidasePrednisoloneRenal DialysisSARS-CoV-2Antibodies, Antineutrophil CytoplasmicAntibodies, Monoclonal, HumanizedCOVID-19 VaccinesImmunosuppressive AgentsMethylprednisolonePeroxidasePrednisoloneBimekizumabCOVID19 vaccinationIL17 antibodyMPO-ANCAPsoriasisRPGN

Identifiers

PMID39297892
PMCPMC11958868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.